PFS rates of female and male patients treated in the RICOVER-60 trial with CHOP-14 with and without rituximab
| . | CHOP-14 . | R-CHOP-14 . |
|---|---|---|
| 2-year PFS, % (95% CI) | ||
| Female patients (n = 287/285) | 62 (56-68) | 77 (72-82) |
| Male patients (n = 325/325) | 61 (56-67) | 71 (66-76) |
| Difference | 1.0 (0.7-1.3) | 5.7 (5.4-6.0) |
| 3-year PFS, % (95% CI) | ||
| Female patients (n = 287/285) | 60 (53-66) | 75 (70-81) |
| Male patients (n = 325/325) | 55 (49-60) | 68 (62-73) |
| Difference | 5.1 (4.8-5.5) | 7.7 (7.4-8.0) |
| 4-year PFS, % (95% CI) | ||
| Female patients (n = 287/285) | 50 (42-58) | 72 (65-78) |
| Male patients (n = 325/325) | 49 (42-56) | 64 (58-70) |
| Difference | 0.9 (0.3-1.5) | 7.6 (7.2-8.0) |
| . | CHOP-14 . | R-CHOP-14 . |
|---|---|---|
| 2-year PFS, % (95% CI) | ||
| Female patients (n = 287/285) | 62 (56-68) | 77 (72-82) |
| Male patients (n = 325/325) | 61 (56-67) | 71 (66-76) |
| Difference | 1.0 (0.7-1.3) | 5.7 (5.4-6.0) |
| 3-year PFS, % (95% CI) | ||
| Female patients (n = 287/285) | 60 (53-66) | 75 (70-81) |
| Male patients (n = 325/325) | 55 (49-60) | 68 (62-73) |
| Difference | 5.1 (4.8-5.5) | 7.7 (7.4-8.0) |
| 4-year PFS, % (95% CI) | ||
| Female patients (n = 287/285) | 50 (42-58) | 72 (65-78) |
| Male patients (n = 325/325) | 49 (42-56) | 64 (58-70) |
| Difference | 0.9 (0.3-1.5) | 7.6 (7.2-8.0) |